April Japanese price cut a mixed bag of give and take
This article was originally published in Scrip
The official release of Japan's new reimbursement tariff showing the revised prices for individual drugs that will come into effect on 1 April reveals a complex mixture of relative impact for products and companies, although as usual the figures are overwhelmingly negative.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.